Merck (MRK) Panoramica del titolo

Merck & Co., Inc. opera come azienda sanitaria a livello mondiale. Maggiori dettagli

MRK analisi fondamentale
Punteggio fiocco di neve
Valutazione	3/6
Crescita futura	4/6
Prestazioni passate	1/6
Salute finanziaria	4/6
Dividendi	4/6

Premi

Negoziato a 48% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 21.21% all'anno

Analisi del rischio

Grandi elementi una tantum che incidono sui risultati finanziari

Il dividendo di 2.78% non è ben coperto dagli utili

I margini di profitto (13.6%) sono inferiori rispetto allo scorso anno (27.3%)

Ha un alto livello di debito

MRK Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Merck & Co., Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Merck
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$27.40
Massimo di 52 settimane	US$28.11
Minimo di 52 settimane	US$17.30
Beta	0.20
Variazione di 1 mese	9.21%
Variazione a 3 mesi	-1.97%
Variazione di 1 anno	50.22%
Variazione a 3 anni	n/a
Variazione a 5 anni	n/a
Variazione dall'IPO	19.97%

Notizie e aggiornamenti recenti

Recent updates

Seeking Alpha • Feb 09

Merck: The Spike Doesn't Make It Overvalued

Summary Merck has surged more than 50% in six months, underpinned by a robust asset portfolio and strong shareholder return strategy. Keytruda, MRK's top-selling drug, faces a 2028 patent cliff, but ongoing innovation and new approvals like Qlex aim to mitigate revenue risk. Despite Gardasil's recent sales decline, MRK's vaccine portfolio remains resilient, with Capvaxive sales up 460% to more than $1 billion annualized. MRK guided for ~$66 billion in 2026 revenue, maintaining a strong dividend yield and buybacks, and pursuing acquisitions to offset Keytruda's patent expiration. Read the full article on Seeking Alpha

Rendimenti per gli azionisti

	MRK	CA Pharmaceuticals	CA Mercato
7D	9.5%	1.3%	1.6%
1Y	50.2%	45.3%	33.7%

Ritorno vs Industria: MRK ha superato il Canadian Pharmaceuticals che ha restituito 45.3 % nell'ultimo anno.

Rendimento vs Mercato: MRK ha superato il mercato Canadian che ha restituito 33.7 % nell'ultimo anno.

Volatilità dei prezzi

Is MRK's price volatile compared to industry and market?
MRK volatility
MRK Average Weekly Movement	4.3%
Pharmaceuticals Industry Average Movement	11.6%
Market Average Movement	10.2%
10% most volatile stocks in CA Market	17.9%
10% least volatile stocks in CA Market	3.9%

Prezzo delle azioni stabile: MRK non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato Canadian.

Volatilità nel tempo: La volatilità settimanale ( 4% ) di MRK è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1891	74,000	Rob Davis	www.merck.com

Merck & Co., Inc. opera come azienda sanitaria a livello mondiale. Opera attraverso due segmenti, quello farmaceutico e quello della salute animale. L'azienda offre prodotti farmaceutici per la salute umana in varie aree, tra cui oncologia, vaccini, assistenza ospedaliera per acuti, cardiovascolare, virologia, neuroscienze e diabete con i marchi Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia e Janumet.

Merck & Co., Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Merck con la sua capitalizzazione di mercato?
MRK statistiche fondamentali
Capitalizzazione di mercato	CA$417.66b
Utili (TTM)	CA$12.34b
Ricavi(TTM)	CA$90.86b

33.8x

Rapporto P/E

4.6x

Rapporto P/S

MRK è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
MRK Conto economico (TTM)
Ricavi	US$65.77b
Costo del fatturato	US$15.31b
Profitto lordo	US$50.46b
Altre spese	US$41.53b
Utili	US$8.94b

Ultimi utili riportati

Mar 31, 2026

Prossima data di guadagno

Aug 04, 2026

Utile per azione (EPS)	3.62
Margine lordo	76.73%
Margine di profitto netto	13.59%
Rapporto debito/patrimonio netto	106.9%

Come si è comportato MRK nel lungo periodo?

Vedi performance storica e confronto

Dividendi

2.8%

Rendimento attuale del dividendo

91%

Rapporto di remunerazione

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2026/05/25 03:34
Prezzo dell'azione a fine giornata	2026/05/22 00:00
Utili	2026/03/31
Utili annuali	2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Merck & Co., Inc. è coperta da 48 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
David Toung	Argus Research Company
Charles Butler	Barclays
Emily Field	Barclays

Merck (MRK) Panoramica del titolo

Premi

Analisi del rischio

Concorrenti di Merck & Co., Inc.

Green Thumb Industries

Novartis

Roche Holding

AstraZeneca

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Sieben Alexander, P.A. Secures $10.2 Million Verdict for Twin Cities Family Against Cosmetic Talc Manufacturers Vi-Jon and Four Co-Defendants—Gold Bond, Merck (Dr. Scholl's), Johnson & Johnson, and Perrigo Co. of Tennessee

Exelixis, Inc. Announces Clinical Development Collaboration with Merck for Phase 3 Stellar-316 Pivotal Trial for Patients with Colorectal Cancer

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints in Advanced or Recurrent Endometrial Cancer

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research At Asco 2026

Merck & Co., Inc. Updates Earnings Guidance for the Full Year 2026

Merck and Eisai Enter Announces FDA Approves Merck’S Once-Daily Idvynso (Doravirine/Islatravir)

Recent updates

Sieben Alexander, P.A. Secures $10.2 Million Verdict for Twin Cities Family Against Cosmetic Talc Manufacturers Vi-Jon and Four Co-Defendants—Gold Bond, Merck (Dr. Scholl's), Johnson & Johnson, and Perrigo Co. of Tennessee

Exelixis, Inc. Announces Clinical Development Collaboration with Merck for Phase 3 Stellar-316 Pivotal Trial for Patients with Colorectal Cancer

Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Meets Primary Endpoints in Advanced or Recurrent Endometrial Cancer

Merck Highlights New Long-Term Data and Advancements Across Broad Oncology Portfolio and Pipeline Research At Asco 2026

Merck & Co., Inc. Updates Earnings Guidance for the Full Year 2026

Merck and Eisai Enter Announces FDA Approves Merck’S Once-Daily Idvynso (Doravirine/Islatravir)

Merck Announces FDA Grants Priority Review For Keytruda And Keytruda Qlex Each With Padcev For Cisplatin-Eligible Patients With Muscle-Invasive Bladder Cancer

Merck Announces European Commission Approval For Enflonsia (Clesrovimab) For Prevention Of Respiratory Syncytial Virus Lower Respiratory Tract Disease In Infants

Daiichi Sankyo And Merck Receive Priority Review For Ifinatamab Deruxtecan In Previously Treated Extensive-Stage Small Cell Lung Cancer

Merck & Co., Inc., Annual General Meeting, May 26, 2026

Merck Announces Initiation of Pivotal Phase 2B/3 Trial Evaluating Mk-8748 for Treatment of Neovascular Age-Related Macular Degeneration

Merck Announces Results for Enlicitide Decanoate, an Investigational Oral Pcsk9 Inhibitor

Merck & Co., Inc. Announces Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction

Merck Reportedly Nears $6 Billion Deal to Buy Terns Pharma

Merck Presents New Data Reinforcing Long-Term Efficacy of Gardasil 9 and Gardasil At Eurogin International Multidisciplinary HPV Congress 2026

Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda

Merck & Co., Inc. Announces KEYTRUDA®? (Pembrolizumab) Plus Padcev®? (enfortumab Vedotin-Ejfv) Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Ejfv

Merck & Co., Inc. Announces Late-Breaking Data from Three Phase 3 Trials Evaluating Doravirine/Islatravir (DOR/ISL) an Investigational, Once-Daily, Two-Drug Regimen for the Treatment of Adults Living with HIV-1 at CROI 2026

Merck & Co., Inc. Announces Executive Appointments and Organizational Changes in Human Health Business

Merck Announces Positive New Data for ENFLONSIA (Caresrovimab) for Infants and Children Under 2 Years of Age At Increased Risk for Severe Respiratory Syncytial Virus Disease over Two RSV Seasons

Merck announces Health Canada Approves KEYTRUDA SC™, a Subcutaneous Formulation of Pembrolizumab Across Multiple Cancer Indications

Merck Advances Treatment of Bladder and Kidney Cancers with New Data At 2026 ASCO GU Cancers Symposium

Merck Announces the U.S. Food and Drug Administration Approves KEYTRUDA (Pembrolizumab and Berahyaluronidase Alfa-Pmph) and KEYTRUDA QLEX

Merck: The Spike Doesn't Make It Overvalued

Merck Announces Health Canada Approval of ENFLONSIA for the Prevention of RSV in Newborns and Infants

Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2026

Merck Declares Dividend on Common Stock for the Second-Quarter of 2026, Payable on April 7, 2026

MSD Reportedly Ends Takeover Talks with Revolution Medicines

Merck Reportedly in Talks to Buy Revolution in Up to $32 Billion Deal

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib in Combination with KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph) in Certain Patients with Advanced NSCLC

Merck Reaches Agreement with U.S. Government to Expand Access to Medicines and Lower Costs for Americans

Merck Announces KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery

Merck Receives Positive EU Chmp Opinion for Expanded Use of Winrevair™? (Sotatercept) in Adults with Pulmonary Arterial Hypertension (Pah, Who* Group 1 Pulmonary Hypertension)

Merck Showcases Data for Alzheimer's Disease Candidates MK-2214 and MK-1167 at CTAD 2025

FDA Approves Merck and KEYTRUDA (Pembrolizumab) and KEYTRUDA QLEX (Pembrolizumab and Berahyaluronidase Alfa-Pmph

Merck Announces Positive Topline Results from the Pivotal Phase 3 Trial Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravir (Dor/Isl) in Treatment-1 Infection

Merck Declares Dividend for the First Quarter of 2026, Payable on January 8, 2026

Merck Reportedly Close on A Deal to Buy Cidara

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Adults with Heterozygous Familial Hypercholesterolemia in Phase 3 CORALreef HeFH Trial

Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly ReducedDL-C in Phase 3 CORALreef Lipids Trial

Merck & Co., Inc. Updates Earnings Guidance for the Year 2025

European Commission Approves KEYTRUDA® (Pembrolizumab) as Part of a Treatment Regimen for Adults with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Expressing PD-L1 (CPS >1)

Merck Announces Positive Topline Results from the Phase 3 LITESPARK-022 Trial in Patients with Clear Cell Renal Cell Carcinoma

Merck & Co., Inc. Receives FDA Approval For Updated Indication Of WINREVAIR In Adults With PAH

Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio At AHA Scientific Sessions 2025

Merck & Co., Inc. Announces the Presentation of Findings from Systematic Review of Studies on the Ep Epiiology and Antimicrobial Resistance of Pneumococcal Serotypes Covered by CapvaXIVE

Merck & Co., Inc. Announces New Long-Term Data Highlighting the Sustained Survival Benefits of Keytruda® (Pembrolizumab), Merck’s anti-PD-1 Therapy, in Treating Non-Small Cell Lung Cancer (NSCLC )

Daiichi Sankyo and Merck Demonstrate Clinically Meaningful Response Rates for Raludotatug Deruxtecan in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Merck and Eisai Announces Long-Term Follow-Up Data Continued to Show Durable Benefit of KEYTRUDA®? (Pembrolizumab) Plus LENVIMA®? (lenvatinib)

Merck & Co., Inc. Announces Phase 3 KEYNOTE-B96 Trial Met Secondary Endpoint of Overall Survival (OS) in All Comers Population of Patients with Platinum-Resistant Recurrent Ovarian Cancer

Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravir/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 Infection

Merck Advances Oncology Innovation, Highlighting Progress in New Tumor Types and Early Stages of Disease At ESMO 2025

Merck Expands Tulisokibart Clinical Development Program with Initiation of Phase 2B Trials in Three Additional Immune-Mediated Inflammatory Diseases

Merck Announces Positive Results from the Phase 3 HYPERION Trial Evaluating Winrevair

FDA Approves Merck’s KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for KEYTRUDA (pembrolizumab)

Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

Daiichi Sankyo and Merck Announce Raludotatug Deruxtecan Receives Breakthrough Therapy Designation by U.S. FDA for Patients with CDH6 Expressing Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancers Previously Treated with Bevacizumab

Merck & Co., Inc. Announces Positive Results from the Phase 3 STRIDE-13 Trial Evaluating CapvaXIVE

Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in Ideate-Lung01 Phase 2 Trial

Merck & Co., Inc. Announces Positive Topline Results from the Phase 3 CORALreef Lipids Trial Evaluating the Safety and Efficacy of Enlicitide Decanoate

Merck's First Patient Dosed in the HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

Daiichi Sankyo and Merck Announce U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer